Alumis trial of lupus drug fails to meet endpoints
Alumis said its phase 2b trial of envudeucitinib for moderate-to-severe systemic lupus erythematosus did not meet its primary or secondary endpoints, including the goal for overall disease activity improvements.
By Katherine HamiltonAlumis said its trial of a lupus treatment didn't meet its primary or secondary endpoints.The phase 2b trial of envudeucitinib as a treatment for moderate-to-severe systemic lupus erythematosus didn't meet the goal of improvements in overall disease activity based on various in…